Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA telbivudine versus tenofovir in HBeAg-negative chronic hepatitis B
2007-000180-13Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Chronic Hepatitis B (CHB) comparing Roadmap-based telbivudine with Roadmap-based tenofovir disoproxil fumarate (2 arms). Primary endpoint: Rate of HBV DNA suppression at week 52. Started Dec 2010; status: completed.
02
Drugs
telbivudinetenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2007-000180-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000180-13.